Contact Us
Find A Doctor

8 Week DEX PS DDS Study Results

An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis

Principal Investigator

C. Michael Samson, MD

Enrollment Status:



To evaluate the safety and efficacy of the 700 μg DEX PS DDS Applicator System (700 μg dexamethasone) compared with the 350 μg DEX PS DDS Applicator System (350 μg dexamethasone) in the treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate uveitis. (700 μg dexamethasone vs. 350 μg dexamethasone)

Study results are currently being analyzed. Please visit this webpage next month for the study update. 

For more information:


Contact Us

Dr. C. Michael Samson, Principal Investigator

Katy Tai, Research ManagerTel: (212) 979-4251

Address310 E. 14th StreetNew York, NY 10003

View all locations